🚀 VC round data is live in beta, check it out!
Adverum Biotechnologies Valuation Multiples
Discover revenue and EBITDA valuation multiples for Adverum Biotechnologies and similar public comparables like Eli Lilly, Johnson & Johnson, AbbVie, Roche and more.
Adverum Biotechnologies Overview
About Adverum Biotechnologies
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Founded
N/A
HQ
—
Employees
N/A
Website
N/A
Financials (LTM)
Market Cap
—
Adverum Biotechnologies Financials
Adverum Biotechnologies reported last 12-month revenue of $1M.
Revenue (LTM)
Adverum Biotechnologies P&L
In the most recent fiscal year, Adverum Biotechnologies reported revenue of — and net income of —.
Adverum Biotechnologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1M | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Adverum Biotechnologies Stock Performance
Adverum Biotechnologies has current market cap of —.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| — | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdverum Biotechnologies Valuation Multiples
Adverum Biotechnologies Financial Valuation Multiples
As of March 11, 2026, Adverum Biotechnologies has market cap of —.
Equity research analysts estimate Adverum Biotechnologies' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 |
|---|
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Adverum Biotechnologies Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Adverum Biotechnologies Margins & Growth Rates
Adverum Biotechnologies' revenue in the last 12 month grew by 0%.
Adverum Biotechnologies Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 0% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Adverum Biotechnologies Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Eli Lilly | XXX | XXX | XXX | XXX | XXX | XXX |
| Johnson & Johnson | XXX | XXX | XXX | XXX | XXX | XXX |
| AbbVie | XXX | XXX | XXX | XXX | XXX | XXX |
| Roche | XXX | XXX | XXX | XXX | XXX | XXX |
| Novartis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adverum Biotechnologies M&A Activity
Adverum Biotechnologies acquired XXX companies to date.
Last acquisition by Adverum Biotechnologies was on XXXXXXXX, XXXXX. Adverum Biotechnologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Adverum Biotechnologies
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdverum Biotechnologies Investment Activity
Adverum Biotechnologies invested in XXX companies to date.
Adverum Biotechnologies made its latest investment on XXXXXXXX, XXXXX. Adverum Biotechnologies invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Adverum Biotechnologies
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Adverum Biotechnologies
| Is Adverum Biotechnologies publicly listed? | Yes, Adverum Biotechnologies is a public company listed on Nasdaq. |
| What is the stock symbol of Adverum Biotechnologies? | Adverum Biotechnologies trades under ADVM ticker. |
| When did Adverum Biotechnologies go public? | Adverum Biotechnologies went public in 2014. |
| Who are competitors of Adverum Biotechnologies? | Adverum Biotechnologies main competitors are Eli Lilly, Johnson & Johnson, AbbVie, Roche. |
| What is the current revenue of Adverum Biotechnologies? | Adverum Biotechnologies' last 12 months revenue is $1M. |
| What is the current revenue growth of Adverum Biotechnologies? | Adverum Biotechnologies revenue growth (NTM/LTM) is 0%. |
| Is Adverum Biotechnologies profitable? | No, Adverum Biotechnologies is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.